Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07509112
PHASE2

Semaglutide for Treatment of People With Methamphetamine Use Disorder: the SHIFT Study

Sponsor: Kirby Institute

View on ClinicalTrials.gov

Summary

Methamphetamine use disorder is a major public health concern in Australia and globally. GLP-1 medications such as semaglutide (e.g. Ozempic) are approved for diabetes and medication, and may potentially affect craving for other substances apart from food. We do not know if this will help people who use methamphetamine ('ice') to reduce their use. This study will treat people who use methamphetamine with weekly injections of semaglutide. It will provide data on if this is a potentially safe and practical treatment for this group of people.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

40

Start Date

2026-05

Completion Date

2027-03

Last Updated

2026-04-03

Healthy Volunteers

No

Interventions

DRUG

12 weeks of weekly subcutaneous semaglutide injection

12 weeks of subcutaneous semaglutide administered once weekly, starting at 0.25 mg once weekly, titrated as tolerated up to 1.0 mg over the 12-week study period.

Locations (5)

Kirketon Road Centre

Darlinghurst, New South Wales, Australia

Rankin Court Treatment Centre, St Vincent's Hospital Sydney

Darlinghurst, New South Wales, Australia

Alcohol & Drug Service, Metro Health North Brisbane

Brisbane, Queensland, Australia

Drug and Alcohol Services, South Australia

Morphett Vale, South Australia, Australia

Next Step Drug and Alcohol Services

East Perth, Western Australia, Australia